The pharmacokinetics of ciprofloxacin and its effect on the oropharyngeal bacterial flora were examined in 21 ill patients being treated for methicillin-resistant Staphylococcus aureus infections or colonization or both. Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 + 1.80 and 0.97 ± 0.81 ,ug/ml and steady-state salivary and nasal secretory concentrations of 1.29 ± 1.0 and 1.84 ± 0.91 ,ig/mI, respectively. Because of technical problems, nasal secretory concentrations were felt to represent rough approximations of true values. Oral ciprofloxacin therapy did not promote colonization of the oropharynx by gram-negative bacilli.
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Even when active in vitro against colonizing strains of methicillin-resistant Staphylococcus aureus, ciprofloxacin is only moderately effective in eliminating the methicillinresistant S. aureus carrier state (6, 7) . Since its limited activity against the methicillin-resistant S. aureus carrier state might be related to poor penetration into mucosal secretions or to an adverse effect on the colonization resistance afforded by the normal flora, we studied the penetration of ciprofloxacin into the mucosal secretions of the upper respiratory tract and characterized alterations of the normal oropharyngeal flora resulting from oral ciprofloxacin therapy.
(This work was presented in part at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, N.Y., 4 to 7 October 1987.)
Twenty-one subjects enrolled in a study to evaluate the therapeutic efficacy of ciprofloxacin (7) were examined. Each received 750 mg of ciprofloxacin orally every 12 h and no other antimicrobial agent during the investigation. Patients fasted for at least 2 h before each dose of ciprofloxacin. Each provided informed consent prior to initiation into the study.
Ciprofloxacin levels in serum, saliva, and nasal secretions were assayed on days 4 to 6 of therapy. Ciprofloxacin concentrations in serum were examined 2 and 10 to 12 h after a ciprofloxacin dose and are referred to hereafter as peak and trough levels, respectively. Nevertheless, it should be noted that since sequential measurements were not obtained, actual peak and trough levels miight have differed slightly from those reported. Ten milliliters of unstimulated saliva was obtained concurrent with the peak level in serum. At this time, preweighed Dacron or cotton pledgets were also placed in each nostril for 15 min. Pledgets were removed, weighed, and then immersed in 1 ml of sterile saline. Nasal secretory concentrations recorded for each subject generally represented a mean concentration of ciprofloxacin in the saline suspensions of two nasal pledgets. However, some pledgets exhibited a decrease in weight after being removed from the nostrils (i.e., were partially retained) and were excluded from analysis. In addition, nasal secretory samples from one patient were excluded from analysis because concentrations of ciprofloxacin detected in these samples were three times higher than those observed in any other nasal specimen examined. All samples were stored at -20°C until ciprofloxacin assays were performed.
Serum samples were analyzed for ciprofloxacin by highpressure liquid chromatography assay by the method of Joos et al. (4) . The protein precipitation step of the Joos method was eliminated when saliva and nasal secretory specimens were analyzed. Separation was performed on a reversephase jiBondapak C18 column (Waters Associates, Inc., Milford, Mass.) at an ambient temperature. Detection was accomplished with an LS-1 fluorescence detector (PerkinElmer Corp., Norwalk, Conn.) equipped with a model 6000A solvent delivery system and a model U6K universal injector. Instrument conditions were sensitivity amplified lOx, a 280-nm excitation wavelength, a 456-nm emission wavelength, a flow rate of 2.5 ml/min, and an injection volume of 5 RI. Validation was achieved by reproducibility studies, using an automatic sample processor (Intelligent Sample Processor 710B; Waters Associates). Between-batch and within-batch recoveries for serum and saliva were >90%, with correlation coefficients for standards curves >0.90 (data not shown). By comparison, ciprofloxacin recovery from nasal pledgets was only 0.41 + 0.05 and was consistent throughout a 3-day validation study. The interday coefficients of variation for the assay were 14.2% at 5.0 pug/ml and 3.1% at 0.5 pg/ml.
Just prior to and on days 4 to 6 of therapy, each subject gargled 10 ml of sterile normal saline which was collected in sterile containers, mixed vigorously, and then diluted 10-fold serially, using normal saline. Samples (0.1 ml) of the dilutions were spread on blood agar, Columbia colistin-nalidixic acid agar, and MacConkey agar. The anaerobic cultures were incubated at 37°C, using the GasPak Plus (BBL Microbiology Systems, Cockeysville, Md.). The cultures were used to quantify total aerobic and anaerobic bacteria, alphahemolytic streptococci, and gram-negative bacilli in each gargle specimen. Gram-negative bacilli were identified to the species level by using MicroScan Neg Combo type 6 panels (American MicroScan, West Sacramento, Calif. Taking into account the 41% recovery of ciprofloxacin from nasal pledgets in validation experiments, the actual steadystate concentration of ciprofloxacin in nasal secretions was calculated to be 1.84 ± 0.91 j,g/ml.
Concentrations of alpha-hemolytic streptococci, total aerobic species, and total anaerobic species in saline gargles all decreased slightly during ciprofloxacin therapy (Fig. 1) . The concentration of alpha-hemolytic streptococci decreased significantly (6.31 ± 1.01 versus 5.81 ± 0.76 log1o CFU/ml; P < 0.05). Three patients were colonized by gram-negative bacilli prior to therapy, two with Serratia marcescens and one with Enterobacter spp. These organisms disappeared from the oropharynx during ciprofloxacin therapy. In no case did new gram-negative bacilli appear in the oropharynx during therapy.
Although considerable data exist concerning the pharmacokinetics of ciprofloxacin in healthy volunteers, little information is available about such pharmacokinetics or the effect of ciprofloxacin on the normal flora in ill patients. Le Bel and colleagues (5) observed peak concentrations in sera from healthy volunteers of 2.26 ± 0.75 ,ug/ml after a single oral ciprofloxacin dose of 500 mg. Peak concentrations in serum increased to 3.51 + 1.33 ,ug/ml after multiple 500-mg doses of ciprofloxacin given orally twice a day. Gonzalez et al. (3) reported peak concentrations in serum of 3.41 to 4.21 ,ug/ml after a single oral dose of 750 mg. OCur peak concentration in serum of 2.56 ± 1.89 ,ug/ml (after multiple 750-mg oral doses given twice daily) was lower than those reported previously (3, 5) . Since we did not perform sequential measurements of ciprofloxacin concentrations in serum, the lower peak concentrations in serum observed in this investigation might simply reflect values lower than the true peak concentrations. The lower peak concentrations in serum might also have reflected differences in gastrointestinal absorption by the various study groups. Both Le Bel et al. (5) and Gonzalez et al. (3) studied healthy volunteers, whereas our subjects were hospitalized patients with numerous debilitating diseases (7) . The difference between our results and those reported in the two previous investigations raises the possibility that the pharmacokinetic information obtained in studies of healthy volunteers might not be directly applicable to debilitated patient populations.
Gonzalez and co-workers (3) observed a steady-state salivary ciprofloxacin concentration of 1.57 ptg/ml in volunteers receiving 750 mg of ciprofloxacin twice daily. The lower salivary concentrations observed in our subjects (1.29 ± 1.0 ,ug/ml) probably reflected lower concentrations in serum. Technical problems involving the collection of nasal secretions prevented us from obtaining precise measurements of nasal secretory ciprofloxacin concentrations. Nevertheless, the data obtained suggest that the penetration of ciprofloxacin into nasal secretions is at least as good as that into saliva.
Although ciprofloxacin entered oral secretions, concentrations appearing in saliva during treatment with 750 mg of ciprofloxacin twice daily led to only minor alterations in the oral flora of our study subjects. Bergan and co-workers (1) have reported a transient suppression of Neisseria spp. in the salivary flora during ciprofloxacin therapy. In neither their study nor ours were alterations of the normal flora severe enough to permit emergence of gram-negative bacilli in the oropharynx. These findings most likely reflect the fact that the steady-state salivary concentration of 1.29 ± 1.0 ,ug/ml observed in the present investigation barely exceeds the reported MICs for alpha-hemolytic streptococci or anaerobic bacteria present in the normal oropharyngeal flora (2) .
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